Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Income Taxes

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Tax Expense (Benefit)

Merck & Co. Inc., income tax expense (benefit), continuing operations

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Federal
Foreign
State
Current provision
Federal
Foreign
State
Deferred provision
Taxes on income from continuing operations

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Current Provision
The current provision exhibits variability over the analyzed periods. It decreased significantly from 2,377 million US dollars in 2020 to 1,334 million US dollars in 2021. Subsequently, there was a sharp increase to 3,486 million US dollars in 2022, followed by a slight decline to 3,411 million US dollars in 2023. The latest figure from 2024 shows an increase to 4,052 million US dollars, indicating a resurgence in current tax expenses.
Deferred Provision
The deferred provision has shown considerable fluctuation and negative values, suggesting deferred tax benefits or credits. Starting with a negative 668 million US dollars in 2020, it became positive at 187 million US dollars in 2021. From 2022 onwards, the deferred provision returned to negative territory, with values of -1,568 million US dollars in 2022, -1,899 million US dollars in 2023, and -1,249 million US dollars in 2024. This pattern indicates a trend of increasing deferred tax benefits that slightly moderated in the last year.
Taxes on Income from Continuing Operations
The total income tax expense from continuing operations varied moderately during the period. It started at 1,709 million US dollars in 2020, with a small decrease to 1,521 million US dollars in 2021. Thereafter, it increased to 1,918 million US dollars in 2022 but declined to 1,512 million US dollars in 2023. The most recent figure in 2024 shows a substantial increase to 2,803 million US dollars, reflecting higher overall tax expenses in that year.
Summary
Overall, there is a notable volatility in both current and deferred tax provisions across the reviewed years. The current provision shows general growth after 2021, while the deferred provision oscillates between positive and negative amounts, generally trending towards increased deferred tax benefits in recent years. The taxes on income from continuing operations mirror this volatility but culminate in a significant rise in 2024, suggesting changes in taxable income or tax policy effects impacting the overall tax expense.

Effective Income Tax Rate (EITR)

Merck & Co. Inc., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
U.S. statutory tax rate
Foreign earnings
Tax settlements and statute lapses
R&D tax credit
Inventory donations
State taxes
Charges for certain research and development asset acquisitions
Valuation allowances
Restructuring
GILTI and the foreign-derived intangible income deduction
Acquisition-related costs, including amortization
Acquisition of Prometheus
Other
Effective tax rate

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


U.S. Statutory Tax Rate
The statutory tax rate remained constant at 21% throughout the five-year period, indicating a stable federal tax policy environment for the company.
Foreign Earnings
Foreign earnings as a percentage showed considerable volatility. Starting at -14.1% in 2020, the figure improved to -10.5% in 2021 but slightly worsened to -11.1% in 2022. There was a significant decline in 2023 to -49.8%, followed by a recovery to -6.5% in 2024. This volatility may reflect fluctuating foreign income or changes in foreign tax regulations affecting reported earnings.
Tax Settlements and Statute Lapses
Tax settlements and statute lapses exhibited a minor overall impact, fluctuating between -2% and near zero, with a missing value in 2023. The negative values suggest occasional beneficial impacts from settlements or lapses, with a more pronounced effect in 2021 and 2024.
R&D Tax Credit
The R&D tax credit percentage varied, beginning at -1.3% in 2020 and decreasing in magnitude to -0.7% in 2022. A sharp increase occurred in 2023 to -11.3%, which then normalized to -1% in 2024. The spike in 2023 implies an unusual or one-time increase in tax credits related to research and development expenditures.
Inventory Donations
Inventory donations as a percentage were generally minor and negative when recorded. Values were missing in 2020, decreased slightly to -0.3% in 2021 and 2022, sharply dropped to -3.5% in 2023, and then rose to -0.4% in 2024. The large dip in 2023 indicates an exceptional level of inventory donations that year.
State Taxes
State taxes showed inconsistency, with positive 0.8% in 2020, a missing value in 2021, followed by negative values in subsequent years: -0.7% in 2022, -6.2% in 2023, and -0.2% in 2024. The negative percentages from 2022 to 2024 indicate a reduction or credit benefit at the state tax level, especially pronounced in 2023.
Charges for Certain Research and Development Asset Acquisitions
This item showed fluctuations, with 7.4% in 2020, dropping to 2.6% in 2021, missing data in 2022, a sharp rise to 13.4% in 2023, and a decline to 2.8% in 2024. The spike in 2023 may relate to significant asset acquisition activities impacting tax charges.
Valuation Allowances
Valuation allowances exhibited a gradual increase from 0.5% in 2020 to 0.7% in 2021 and 2022, followed by a substantial rise to 3.7% in 2023, and a sharp decline to 0.3% in 2024. The 2023 increase may reflect adjustments for potential asset impairments or deferred tax considerations.
Restructuring
Restructuring charges as percentages were relatively low and stable, moving from 1.2% in 2020 to 0.4% in 2021, 0.1% in 2022, increasing to 2.2% in 2023, and declining to 0.3% in 2024. The 2023 increase may signify a notable restructuring effort during that year.
GILTI and Foreign-Derived Intangible Income Deduction
These tax components demonstrated variability, with 4.1% in 2020, a negative effect of -0.5% in 2021, rebounding to 2.8% in 2022, a negative impact of -4.3% in 2023, and a near-neutral 0.1% in 2024. This suggests fluctuating impacts from international tax provisions and deductions over the period.
Acquisition-Related Costs, Including Amortization
Acquisition-related costs were minimal and inconsistent: 0.5% in 2020, 0.1% in 2021, missing in 2022, increased to 2.2% in 2023, and 0.1% in 2024. The spike in 2023 likely relates to specific acquisition activities.
Acquisition of Prometheus
This item was only recorded in 2023, showing a significant figure of 113.3%, with no data before or after. This indicates a one-time, substantial acquisition event impacting the financial data for that particular year.
Other
Other items fluctuated slightly around zero, with minor negative values in 2020 (-0.5%) and 2023 (-0.7%), positive values in 2021 (0.3%) and 2024 (0.4%), and missing data in 2022, indicating small miscellaneous effects on the overall financials.
Effective Tax Rate
The effective tax rate exhibited noteworthy fluctuations. Starting at 19.4% in 2020, it decreased sharply to 11% in 2021 and remained near that level at 11.7% in 2022. A dramatic spike occurred in 2023, reaching 80%, followed by a return to 14.1% in 2024. The spike corresponds with the significant acquisition of Prometheus and related costs, underscoring a one-time tax impact during that period.

Components of Deferred Tax Assets and Liabilities

Merck & Co. Inc., components of deferred tax assets and liabilities

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Product intangibles and licenses
R&D capitalization
Inventory related
Undistributed foreign earnings
Pensions and other postretirement benefits
Compensation related
Unrecognized tax benefits
Net operating losses and other tax credit carryforwards
Other
Gross deferred income tax assets
Valuation allowance
Deferred income tax assets
Product intangibles and licenses
Inventory related
Accelerated depreciation
Undistributed foreign earnings
Equity investments
Pensions and other postretirement benefits
Other
Deferred income tax liabilities
Net deferred income taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The analysis of the annual financial data reveals several noteworthy trends related to deferred tax assets, liabilities, and associated components over the five-year period.

Deferred Tax Assets

Gross deferred income tax assets fluctuated significantly, decreasing from 2,989 million USD in 2020 to 2,283 million USD in 2021, then rising sharply to 5,980 million USD by 2024. This overall upward trend indicates a growing recognition of potential tax benefits.

Within this category, "R&D capitalization" showed a substantial increase from 1,341 million USD in 2022 up to 3,062 million USD in 2024, reflecting an increasing capitalization of research and development expenditures.

Other specific asset components such as "Inventory related" and "Compensation related" increased moderately toward 2024, with compensation-related assets rising steadily from 252 million USD in 2020 to 400 million USD in 2024.

Conversely, "Pensions and other postretirement benefits" assets declined from 834 million USD in 2020 to 224 million USD in 2024, marking a clear downward trajectory in this specific asset category.

Valuation Allowance and Net Deferred Income Tax Assets

The valuation allowance, representing reserves against deferred tax assets, generally increased in magnitude from -433 million USD in 2020 to -710 million USD in 2024, indicating a more conservative stance regarding realizability of deferred tax assets.

Net deferred income taxes showed a volatile pattern, starting negative at -121 million USD in 2020, dipping further to -2,749 million USD in 2021, then progressively increasing to a positive 2,214 million USD in 2024. This shift from a net liability position into a net asset position suggests improvement in deferred tax balances over time.

Deferred Tax Liabilities

Deferred income tax liabilities demonstrated a declining trend, moving from -2,677 million USD in 2020 to -3,056 million USD in 2024, with a trough at -4,745 million USD in 2021. This indicates a fluctuating yet generally large liability position that somewhat decreased toward the end of the period.

Specific liability components such as "Product intangibles and licenses" saw a reduction in negative balances, improving from -1,250 million USD in 2020 to -978 million USD in 2024.

Other Components

The "Undistributed foreign earnings" showed emerging deferred tax assets and liabilities starting in 2024, with a 275 million USD asset against a -371 million USD liability, highlighting new tax considerations related to foreign earnings.

"Equity investments" liabilities fluctuated without a clear linear trend, suggesting variability in tax positions relating to investment holdings.

"Unrecognized tax benefits" increased steadily from 117 million USD in 2020 to 152 million USD in 2024, indicating rising amounts of uncertain tax positions.

Overall, the data depict growing deferred tax assets predominantly driven by increased R&D capitalization and deferred tax asset recognition. Concurrently, valuation allowances increased, reflecting caution toward asset realization. The net deferred tax position improved markedly, moving from a net liability to a net asset over the period. Deferred tax liabilities, although large and fluctuating, showed signs of reduction in certain categories such as product intangibles and licenses. The emergence of new items in 2024 related to foreign earnings signals evolving tax considerations in the international context.


Deferred Tax Assets and Liabilities, Classification

Merck & Co. Inc., deferred tax assets and liabilities, classification

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Deferred income tax assets (included in Other assets)
Deferred income tax liabilities

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data over the five-year period indicates notable fluctuations in both deferred income tax assets and liabilities.

Deferred Income Tax Assets
The deferred income tax assets show a declining trend from 2020 through 2022, starting at 894 million USD in 2020, decreasing to 692 million USD in 2021 and further to 503 million USD in 2022. However, a significant reversal occurs from 2022 onwards, with assets sharply increasing to 1,968 million USD in 2023 and almost doubling to 3,601 million USD by the end of 2024. This uptick suggests either improved recognition of deductible temporary differences or changes in tax positions that result in higher deferred tax asset values.
Deferred Income Tax Liabilities
The deferred income tax liabilities show more volatility during the observed period. In 2020, liabilities stood at 1,015 million USD, followed by a marked increase to 3,441 million USD in 2021. In 2022, the liabilities declined significantly to 1,795 million USD, then continued dropping to 871 million USD in 2023. In 2024, the liabilities rose again to 1,387 million USD. This pattern may reflect the impact of changes in accounting estimates, tax law, or timing differences related to the recognition of taxable temporary differences.

Overall, the deferred tax assets experienced an initial decrease followed by a substantial rise, while the deferred tax liabilities exhibited high volatility with an increase in 2021, subsequent decreases through 2023, and a moderate rebound in 2024. The fluctuations in both items could be linked to strategic tax planning, changes in tax regulations, or operational factors affecting the timing differences between accounting and taxable income.


Adjustments to Financial Statements: Removal of Deferred Taxes

Merck & Co. Inc., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Adjustment to Total Assets
Total assets (as reported)
Less: Noncurrent deferred tax assets, net
Total assets (adjusted)
Adjustment to Total Liabilities
Total liabilities (as reported)
Less: Noncurrent deferred tax liabilities, net
Total liabilities (adjusted)
Adjustment to Total Merck & Co., Inc. Stockholders’ Equity
Total Merck & Co., Inc. stockholders’ equity (as reported)
Less: Net deferred tax assets (liabilities)
Total Merck & Co., Inc. stockholders’ equity (adjusted)
Adjustment to Net Income Attributable To Merck & Co., Inc.
Net income attributable to Merck & Co., Inc. (as reported)
Add: Deferred income tax expense (benefit)
Net income attributable to Merck & Co., Inc. (adjusted)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Total Assets
The reported total assets demonstrate a general upward trend from 91,588 million US dollars in 2020 to 117,106 million US dollars in 2024, with a slight decline observed in 2023. Adjusted total assets follow a similar pattern, rising from 90,694 million US dollars in 2020 to 113,505 million US dollars in 2024 but also exhibiting a minor decrease in 2023. Overall, both reported and adjusted total assets increased significantly over the five-year period.
Total Liabilities
Reported total liabilities show fluctuations with an initial increase from 66,184 million US dollars in 2020 to 67,437 million in 2021, a decrease to 63,102 million in 2022, followed by increases in 2023 and 2024, reaching 70,734 million US dollars. Adjusted total liabilities reflect a comparable pattern, decreasing in 2022 to 61,307 million US dollars before rising again to 69,347 million in 2024. There is an overall moderate increase in liabilities over the period despite some variability.
Stockholders' Equity
Reported stockholders’ equity displays considerable variability, increasing sharply from 25,317 million US dollars in 2020 to 45,991 million in 2022, then declining to 37,581 million in 2023 before rebounding to 46,313 million in 2024. Adjusted stockholders’ equity follows a similar trend, peaking at 47,283 million in 2022, dipping to 36,484 million in 2023, and rising again to 44,099 million in 2024. The pattern indicates significant changes in equity components, particularly a pronounced dip in 2023.
Net Income
Reported net income attributable to the company exhibits substantial variability. It increased from 7,067 million US dollars in 2020 to a peak of 14,519 million in 2022, then sharply declined to 365 million in 2023 before rising again to 17,117 million in 2024. Adjusted net income shows a somewhat different trajectory: rising steadily from 6,399 million in 2020 to 13,236 million in 2021, then declining to 12,951 million in 2022, turning negative at -1,534 million in 2023, and recovering to 15,868 million in 2024. This suggests the presence of significant non-recurring items or adjustments affecting the 2023 results.
Overall Insights
Over the analyzed period, the company experienced growth in total assets alongside fluctuating liabilities and equity levels. The pronounced dips in 2023 across adjusted net income, equity, and assets likely reflect specific one-time events or adjustments impacting that fiscal year. The recovery in 2024 across most financial metrics indicates a return to stronger financial performance following this period of volatility.

Merck & Co. Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Merck & Co. Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Net Profit Margin
The reported net profit margin demonstrated considerable volatility over the period. It increased markedly from 14.72% in 2020 to a peak of 26.79% in 2021, followed by a moderate decline to 24.49% in 2022. A sharp decrease to 0.61% was observed in 2023 before rebounding to a strong 26.68% in 2024. The adjusted net profit margin closely mirrored this trend, although it reflected a more pronounced dip into negative territory at -2.55% in 2023, recovering to 24.73% in 2024.
Total Asset Turnover
The reported total asset turnover ratio showed a mild declining trend from 0.52 in 2020 to 0.46 in 2021, before increasing to 0.54 in 2022 and maintaining a relatively stable level around 0.55-0.56 through 2023 and 2024. The adjusted ratios were highly consistent with reported figures and indicated a slight improvement in asset utilization efficiency in the latter years, rising gradually to 0.57 in 2023 and 2024.
Financial Leverage
A declining trend in financial leverage was evident over most of the period, with reported leverage falling from 3.62 in 2020 to a low of 2.37 in 2022. This downward trend was interrupted in 2023 when leverage increased to 2.84, before decreasing again to 2.53 in 2024. Adjusted leverage ratios reflect a similar pattern, with the most notable variation being a slight increase beyond reported figures in 2023.
Return on Equity (ROE)
Reported ROE increased markedly from 27.91% in 2020 to 34.17% in 2021, followed by a moderate decline to 31.57% in 2022. It dropped sharply to 0.97% in 2023 but recovered strongly to 36.96% in 2024. Adjusted ROE followed the same overall trajectory but demonstrated a deeper decline into negative territory at -4.2% in 2023. The rebound in 2024 was similarly strong at 35.98%.
Return on Assets (ROA)
The reported ROA showed steady improvement from 7.72% in 2020 to a high of 13.3% in 2022. However, a steep decline to 0.34% occurred in 2023, followed by a strong recovery to 14.62% in 2024. The adjusted ROA mirrored these trends but exhibited a negative return at -1.47% in 2023. The recovery in 2024 brought the adjusted ROA back to a level close to 14%.
Overall Analysis
The financial data indicates strong growth and profitability from 2020 to 2022, followed by a significant decline in 2023 across multiple key performance indicators, including net profit margin, ROE, and ROA. The 2023 downturn was marked by negative adjusted results, suggesting the impact of exceptional or non-recurring items affecting profitability when adjustments for deferred tax effects were considered. Total asset turnover remained relatively stable, with signs of modest improvement in later years. Financial leverage decreased over the period with a temporary rise in 2023, possibly reflecting changes in capital structure during the downturn. The sharp recovery in 2024 across most metrics suggests a return to favorable operating conditions or successful management interventions post-2023 challenges.

Merck & Co. Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Sales
Profitability Ratio
Net profit margin1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Merck & Co., Inc.
Sales
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Net profit margin = 100 × Net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Sales
= 100 × ÷ =


Reported Net Income Attributable to Merck & Co., Inc.
The reported net income demonstrates a generally upward trend from 2020 through 2024, with the exception of 2023, where there is a significant decline to 365 million US dollars. The values start at 7,067 million in 2020, increase substantially to 13,049 million in 2021, and further to 14,519 million in 2022. After dropping sharply in 2023, the net income recovers strongly to reach 17,117 million in 2024, surpassing previous years.
Adjusted Net Income Attributable to Merck & Co., Inc.
The adjusted net income follows a similar upward trajectory initially, increasing from 6,399 million in 2020 to a peak of 13,236 million in 2021, though it decreases slightly to 12,951 million in 2022. There is a pronounced downturn in 2023, with adjusted net income becoming negative at -1,534 million. In 2024, the figure rebounds positively to 15,868 million, indicating recovery but with some volatility over the observed period.
Reported Net Profit Margin
The reported net profit margin exhibits substantial fluctuation over the years. Starting at 14.72% in 2020, it nearly doubles to 26.79% in 2021 and slightly declines to 24.49% in 2022. The margin collapses dramatically to 0.61% in 2023 before a strong recovery to 26.68% in 2024. This pattern closely mirrors the reported net income trend, reflecting significant operational or one-time impacts in 2023.
Adjusted Net Profit Margin
The adjusted net profit margin shows a similar volatility pattern to the reported margin but with more pronounced negative performance in 2023. It rises from 13.33% in 2020 to 27.18% in 2021 and then declines to 21.85% in 2022. In 2023, the margin falls sharply to -2.55%, indicating a loss on an adjusted basis. The margin recovers to a positive 24.73% in 2024 but remains below the 2021 level, suggesting some lingering effects from the challenging period.
Insights
The data reveals a generally positive financial performance across most years with significant disruption in 2023, where both reported and adjusted metrics display sharp declines. The recovery observed in 2024 indicates resilience, though the volatility suggests potential underlying factors such as one-time expenses, changes in tax treatment, or operational challenges impacting profitability. Margins align closely with net income trends, emphasizing the impact on overall profitability during the fiscal periods assessed. Adjusted data points, which exclude certain items, show somewhat greater volatility, particularly with a negative margin and net income in 2023, underscoring possibly substantial non-recurring or deferred tax impacts within that year.

Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Sales
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Sales
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Total asset turnover = Sales ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Sales ÷ Adjusted total assets
= ÷ =


The analysis of the financial data reveals several notable trends over the five-year period examined.

Total Assets
Reported total assets show a general upward trend from 91,588 million US dollars in 2020 to 117,106 million US dollars in 2024, indicating consistent asset growth over the period. There is a slight decline noted in 2023 compared to 2022, where reported assets decreased from 109,160 million to 106,675 million. However, this decline is followed by a substantial recovery in 2024.
Adjusted total assets, which account for deferred income tax adjustments, follow a similar growth pattern, rising from 90,694 million US dollars in 2020 to 113,505 million US dollars in 2024. Like reported total assets, adjusted assets also experience a minor dip in 2023 before increasing again the following year. The adjusted figures are consistently slightly lower than the reported values across all periods, reflecting the impact of tax adjustments.
Total Asset Turnover
Reported total asset turnover exhibits some fluctuation, starting at 0.52 in 2020, declining to 0.46 in 2021, and then improving to 0.54 in 2022. The upward momentum continues in 2023 with 0.56, though there is a slight decrease to 0.55 in 2024. This indicates that the company's efficiency in using its assets to generate revenue improved after the initial dip in 2021 but faced a minor reduction in the last year analyzed.
Adjusted total asset turnover closely mirrors the reported figures, with a similar decline in 2021 to 0.46, followed by an upward trend reaching 0.57 in both 2023 and 2024. The adjusted turnover ratio is marginally higher than the reported ratio in the final years, suggesting a slightly better efficiency measurement when accounting for deferred tax adjustments.

Overall, the data points to a company that is incrementally growing its asset base, managing to improve asset utilization efficiency after an initial setback, with deferred income tax adjustments marginally affecting asset valuations and turnover measurements. The minor fluctuations in 2023 may warrant further investigation to understand underlying causes, but the general trajectory suggests strengthening asset management and operational efficiency.


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= ÷ =


The financial data reveals several key trends in the assets, equity, and leverage of the company over a five-year period.

Assets
Reported total assets increased consistently from 91,588 million US dollars in 2020 to 117,106 million US dollars in 2024, indicating steady growth over the period. The adjusted total assets follow a similar trajectory, starting at 90,694 million and reaching 113,505 million US dollars by 2024. Despite minor fluctuations, the adjusted figures remain close to the reported amounts, suggesting limited impact from tax adjustments on total asset valuation.
Stockholders’ Equity
Reported stockholders’ equity experienced notable fluctuations. It rose sharply from 25,317 million US dollars in 2020 to a peak of 45,991 million in 2022, then declined significantly to 37,581 million in 2023 before increasing again to 46,313 million in 2024. The adjusted stockholders’ equity figures parallel this pattern, though the 2023 dip is more pronounced, falling from 47,283 million in 2022 to 36,484 million, and recovering to 44,099 million by 2024. This volatility may reflect changes in retained earnings, equity issuance or repurchases, or tax-related adjustments impacting equity values.
Financial Leverage
The financial leverage ratios, both reported and adjusted, show a general downward trend from 2020 through 2022, indicating a reduction in leverage or an improvement in the equity base relative to assets. Reported leverage declined from 3.62 in 2020 to 2.37 in 2022 while adjusted leverage fell from 3.57 to 2.30 in the same period. However, in 2023, leverage levels rose again, with reported leverage increasing to 2.84 and adjusted leverage to 2.87, before moderating slightly in 2024 to 2.53 (reported) and 2.57 (adjusted). This suggests a temporary increase in debt or reduction in equity during 2023, followed by stabilization.

Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
ROE1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Merck & Co., Inc.
Adjusted total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =


Net Income Trends
Reported net income attributable to Merck & Co., Inc. experienced a substantial increase from 7,067 million US$ in 2020 to 13,049 million US$ in 2021, followed by a continuing rise to 14,519 million US$ in 2022. There was a significant decline in 2023 to 365 million US$, after which net income rebounded strongly to 17,117 million US$ in 2024. Adjusted net income showed a similar upward trend from 6,399 million US$ in 2020 to 13,236 million US$ in 2021 but then decreased to 12,951 million US$ in 2022. A notable drop occurred in 2023 with a negative result of -1,534 million US$, followed by a recovery to 15,868 million US$ in 2024.
Stockholders’ Equity Evolution
Reported total stockholders’ equity increased steadily from 25,317 million US$ in 2020 to 38,184 million US$ in 2021 and further to 45,991 million US$ in 2022. In 2023, this value declined to 37,581 million US$ but rose again to 46,313 million US$ in 2024. Adjusted equity displayed a generally consistent trend, increasing from 25,438 million US$ in 2020 to 40,933 million US$ in 2021 and to 47,283 million US$ in 2022. It then decreased to 36,484 million US$ in 2023, with a slight recovery to 44,099 million US$ in 2024.
Return on Equity (ROE) Patterns
Reported ROE exhibited strong performance from 27.91% in 2020 to 34.17% in 2021 and 31.57% in 2022, followed by a sharp decrease to 0.97% in 2023. It then increased significantly to 36.96% in 2024. Adjusted ROE mirrored this pattern, rising from 25.16% in 2020 to 32.34% in 2021 before falling to 27.39% in 2022. In 2023, adjusted ROE was negative at -4.2%, indicating a loss relative to equity, but it improved to 35.98% in 2024.
Overall Analysis
The financial data indicates positive growth in net income and equity through 2021 and 2022, demonstrating solid profitability and capitalization. However, 2023 marked a period of significant decline in earnings and returns, with adjusted figures showing losses and reduced equity levels. This could suggest exceptional or one-time challenges affecting profitability that year. The strong recovery in 2024 across almost all metrics suggests a return to favorable operating conditions and improved financial health.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total assets
Profitability Ratio
ROA1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Merck & Co., Inc.
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income attributable to Merck & Co., Inc. ÷ Adjusted total assets
= 100 × ÷ =


Net Income Trends
The reported net income showed a significant increase from 7,067 million USD in 2020 to 13,049 million USD in 2021, continuing to rise to 14,519 million USD in 2022. However, in 2023, there was a sharp decline to 365 million USD, followed by a recovery to 17,117 million USD in 2024. The adjusted net income followed a similar upward trend initially, increasing from 6,399 million USD in 2020 to 13,236 million USD in 2021, but then experienced a decrease in 2022 to 12,951 million USD. In 2023, the adjusted net income turned negative, recording -1,534 million USD, before rebounding to 15,868 million USD in 2024. This suggests that while the overall profitability improved over the early years, 2023 presented a challenging period, particularly reflected in the adjusted figures, followed by a strong recovery in 2024.
Total Assets
Reported total assets demonstrated a steady increase over the years, starting at 91,588 million USD in 2020 and reaching 117,106 million USD by 2024, despite a slight dip in 2023 to 106,675 million USD. Adjusted total assets show a similar pattern, growing from 90,694 million USD in 2020 to 113,505 million USD in 2024, with a minor decrease in 2023 to 104,707 million USD. The consistent upward trend indicates an overall growth in the asset base, with only a small contraction in 2023 that might correspond to the disruptions seen in profitability metrics during the same year.
Return on Assets (ROA)
The reported return on assets (ROA) improved substantially from 7.72% in 2020 to 12.35% in 2021, peaking at 13.3% in 2022. In 2023, ROA collapsed drastically to 0.34%, before rebounding to 14.62% in 2024. Adjusted ROA followed a related pattern with initial growth from 7.06% in 2020 to 12.61% in 2021, but then a decline to 11.92% in 2022. The adjusted figure reflected a negative return in 2023 at -1.47%, surpassing the severity shown in reported ROA, before recovering to 13.98% in 2024. This volatility suggests that asset efficiency and profitability were severely impaired in 2023 but improved remarkably by 2024, aligning with the trends observed in net income.
Overall Analysis
The analysis indicates that the company experienced robust growth in net income, asset base, and profitability performance between 2020 and 2022. However, 2023 marked a year of significant difficulties with sharp declines in reported and adjusted net income and ROA, as well as a modest contraction in total assets. This downturn was followed by a notable recovery in 2024, characterized by record-high net income and strong returns on assets. The divergence between reported and adjusted figures, especially the negative adjusted income and ROA in 2023, highlights the effects of certain adjustments or non-recurring items during that year, suggesting an extraordinary event or period-specific issues impacting financial performance. The asset growth across the period underlines continued investment and expansion despite the temporary profit challenges observed.